Christopher Silber Selected Research

zuranolone

1/2022	A phase 1 double-blind, placebo-controlled study of zuranolone (SAGE-217) in a phase advance model of insomnia in healthy adults.
1/2022	Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
2/2021	Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study.
1/2021	Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
1/2019	Trial of SAGE-217 in Patients with Major Depressive Disorder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher Silber Research Topics

Disease

2	Headache (Headaches) 01/2022 - 01/2019
2	Major Depressive Disorder (Major Depressive Disorders) 01/2022 - 01/2019
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2022
1	Fatigue 01/2022
1	Tremor (Tremors) 02/2021
1	Confusion (Bewilderment) 01/2021
1	Postpartum Depression (Post-Natal Depression) 01/2021
1	Pancreatitis 01/2021
1	Sleepiness 01/2019
1	Dizziness (Lightheadedness) 01/2019
1	Nausea 01/2019

Drug/Important Bio-Agent (IBA)

5	zuranoloneIBA 01/2022 - 01/2019
1	Dopamine Agents (Dopaminergic Agents)IBA 02/2021
1	nasIBA 02/2021
1	Dopamine (Intropin)FDA LinkGeneric 02/2021
1	Tuberculin (PPD)IBA 01/2021
1	gamma-Aminobutyric Acid (GABA)IBA 01/2019

Therapy/Procedure

1	Therapeutics 02/2021